Renaissance Technologies’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-17,905
| Closed | -$23.6K | – | 4025 |
|
|
2024
Q3 | $23.6K | Buy |
17,905
+700
| +4% | +$3.38K | ﹤0.01% | 3419 |
|
|
2024
Q2 | $131K | Buy |
17,205
+300
| +2% | +$2.58K | ﹤0.01% | 3134 |
|
|
2024
Q1 | $152K | Buy |
16,905
+545
| +3% | +$4.79K | ﹤0.01% | 3287 |
|
|
2023
Q4 | $175K | Buy |
16,360
+695
| +4% | +$5.01K | ﹤0.01% | 3176 |
|
|
2023
Q3 | $94K | Buy |
15,665
+1,315
| +9% | +$9.26K | ﹤0.01% | 3263 |
|
|
2023
Q2 | $99K | Buy |
14,350
+1,595
| +13% | +$10.5K | ﹤0.01% | 3480 |
|
|
2023
Q1 | $200K | Buy |
12,755
+665
| +6% | +$13.1K | ﹤0.01% | 3281 |
|
|
2022
Q4 | $242K | Sell |
12,090
-36,900
| -75% | -$735K | ﹤0.01% | 3331 |
|
|
2022
Q3 | $874K | Buy |
48,990
+16,803
| +52% | +$360K | ﹤0.01% | 2578 |
|
|
2022
Q2 | $715K | Buy |
32,187
+4,997
| +18% | +$111K | ﹤0.01% | 2925 |
|
|
2022
Q1 | $756K | Buy |
27,190
+8,363
| +44% | +$304K | ﹤0.01% | 2910 |
|
|
2021
Q4 | $855K | Buy |
18,827
+11,687
| +164% | +$786K | ﹤0.01% | 2765 |
|
|
2021
Q3 | $595K | Buy |
7,140
+4,530
| +174% | +$375K | ﹤0.01% | 2817 |
|
|
2021
Q2 | $248K | Buy |
+2,610
| New | +$310K | ﹤0.01% | 3200 |
|
|
2021
Q1 | – | Sell |
-4,928
| Closed | -$483K | – | 3816 |
|
|
2020
Q4 | $483K | Sell |
4,928
-2,456
| -33% | -$155K | ﹤0.01% | 2835 |
|
|
2020
Q3 | $251K | Buy |
7,384
+3,982
| +117% | +$195K | ﹤0.01% | 3054 |
|
|
2020
Q2 | $193K | Buy |
3,402
+2,036
| +149% | +$115K | ﹤0.01% | 3172 |
|
|
2020
Q1 | $80K | Buy |
1,366
+317
| +30% | +$23.7K | ﹤0.01% | 3263 |
|
|
2019
Q4 | $83K | Buy |
+1,049
| New | +$109K | ﹤0.01% | 3341 |
|
|
2019
Q2 | – | Sell |
-1,677
| Closed | -$282K | – | 3803 |
|
|
2019
Q1 | $282K | Buy |
+1,677
| New | +$250K | ﹤0.01% | 3112 |
|
|
2018
Q3 | – | Sell |
-548
| Closed | -$1.17M | – | 3620 |
|
|
2018
Q2 | $1.17M | Buy |
548
+25
| +5% | +$63.4K | ﹤0.01% | 2537 |
|
|
2018
Q1 | $1.3M | Buy |
+523
| New | +$1.17M | ﹤0.01% | 2539 |
|
|
2016
Q4 | – | Sell |
-52
| Closed | -$57K | – | 3524 |
|
|
2016
Q3 | $57K | Buy |
+52
| New | +$45.4K | ﹤0.01% | 3245 |
|
|
2014
Q1 | – | Sell |
-13
| Closed | -$30K | – | 3062 |
|
|
2013
Q4 | $30K | Buy |
+13
| New | +$29.7K | ﹤0.01% | 2803 |
|
|
2013
Q3 | – | Sell |
-38
| Closed | -$356K | – | 2983 |
|
|
2013
Q2 | $356K | Buy |
+38
| New | +$293K | ﹤0.01% | 2351 |
|
Other funds holding ONCT
Renaissance Technologies's ONCT Position: Q4 2024 in Review
Renaissance Technologies sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 17,905 shares — an estimated $23.6K sold.
Renaissance Technologies first reported a position in ONCT in Q2 2013 and held it in 25 quarters. The position peaked at $1.3M in Q1 2018. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.
- Renaissance Technologies reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Renaissance Technologies sold 17,905 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $23.6K.
- Renaissance Technologies first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
- Renaissance Technologies's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.3M in Q1 2018.
- 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.